Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3865347 | The Journal of Urology | 2011 | 5 Pages |
Abstract
Sipuleucel-T therapy in patients with prostate cancer has a side effect profile that is characterized by mild to moderate, short-term, reversible adverse events. There was no evidence of a treatment related increase in autoimmune complications or secondary malignancies after treatment with sipuleucel-T. Sipuleucel-T can be administered safely in the outpatient setting.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Simon J. Hall, Laurence Klotz, Allan J. Pantuck, Daniel J. George, James B. Whitmore, Mark W. Frohlich, Robert B. Sims,